{
    "root": "89f5bf68-ee29-42a9-91ff-fa08fae05a1d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Buprenorphine",
    "value": "20240101",
    "ingredients": [
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        }
    ],
    "indications": "Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.",
    "contraindications": "Administer buprenorphine sublingual tablets sublingually as a single daily dose. ( 2.2 ) Strongly consider prescribing naloxone at the time buprenorphine sublingual tablets are initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. ( 2.3 ) To avoid precipitating withdrawal, induction with buprenorphine sublingual tablets should be undertaken when objective and clear signs of withdrawal are evident. ( 2.4 ) Buprenorphine and naloxone sublingual film or buprenorphine and naloxone sublingual tablet is generally initiated after two days of buprenorphine sublingual tablets titration. ( 2.5 ) Administer buprenorphine sublingual tablets as directed in the Full Prescribing Information. ( 2.4 , 2.5 , 2.6 ) Buprenorphine sublingual tablets must be administered whole. Do not cut, chew, or swallow buprenorphine sublingual tablets. ( 2.6 ) When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. ( 2.10 )",
    "warningsAndPrecautions": "Buprenorphine sublingual tablets are available as follows:\n                  2 mg – Orange, oval tablets debossed with  on one side and 156 on the other side. Tablets are supplied in bottles of 30 (NDC 0228-3156-03).\n                  8 mg –    Orange, oval tablets debossed with  on one side and 153 on the other side. Tablets are supplied in bottles of 30 (NDC 0228-3153-03).\n                  Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in USP.\n                  Store buprenorphine sublingual tablets securely and dispose of properly [see Patient Counseling Information (17)].",
    "adverseReactions": "Buprenorphine sublingual tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions \n                     (\n                     \n                        5.9\n                     \n                     )\n                     ]\n                     ."
}